Neumorphism white abstract eye _edited.jpg

Newsroom

Discover PulseMedica in the news! Read company announcements, development progress, and more.

Featured in

Recent News Story

May 7, 2026

Most Edmonton Startup of the Year Award

PulseMedica recognized as the "Most Edmonton Startup of the Year" by YEG Startup Community Awards.

Learn More

PulseMedica in the News

Published by:

INOVAIT

Jan 26, 2024

PulseMedica is Laser-Focused on Tackling Vitreoretinal Diseases

PulseMedica aims to transform vitreoretinal disease outcomes in the blink of an eye.

Read Article

Published by:

Taproot Edmonton

Mar 30, 2022

PulseMedica raises $2.6M as it prepares to launch laser treatment trial

PulseMedica has raised an oversubscribed $2.6-million seed round, which it largely plans to use to run its first clinical trial beginning in June. The University of Alberta spinoff company is working on a new way to treat patients with major eye diseases.

Read Article

Published by:

Alberta Innovates

Jan 11, 2024

AICE Validate Program Success Story

Alberta Innovates supports companies like PulseMedica as they develop technology to make our lives better.

Watch Video

Published by:

Ophthalmology Innovation Source

Feb 2, 2022

A Laser-Focused Business Model, with Nir Katchinskiy, PhD and Lahav Gil

The OIS podcast features leaders and drivers of ophthalmic innovation from around the world. In January 2022, PulseMedica’s CEO Nir Katchinskiy and Advisor Lahav Gil joined Dr. Ehsan Sadri MD FACS on the Ophthalmology Innovation Source (OIS) podcast.

Listen Now

Published by:

Optics.org

Apr 4, 2022

PulseMedica closes $2.6M seed round

Early-stage financing for Canadian startup developing ultrafast laser treatment of several eye diseases.

Read Article

Published by:

Startup TNT

Nov 19, 2021

PulseMedica, Winner of the TNT Investment Summit

A company that’s working on a revolutionary solution for patients suffering from major eye diseases took home the top prize in the Edmonton third of Startup TNT’s Investment Summit IV.

Read Article

5
Page 4